LY2090314

SKU: orb1307529

Description

LY2090314 is a potent and selective GSK-3α/β inhibitor (IC50: 1.5 nM/0.9 nM) investigated for its potential to enhance platinum chemotherapy. It has been studied in preclinical models and clinical trials for applications in leukemia, advanced solid tumors, and pancreatic cancer research.

Research Area

Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 603288-22-8
• MW: 512.53
• Purity: 99.91%
• Formula: C₂₈H₂₅FN₆O₃
• SMILES: Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1
• Target: GSK-3
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.9 mM);DMSO:35.36 mg/mL (68.99 mM);Ethanol:2 mg/mL (3.9 mM)

Bioactivity

• Target IC50:
  GSK-3β:0.9 nM|GSK-3α:1.5 nM
• In Vivo:
  LY2090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer xenografts.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Glycogen synthase kinase 3, Glycogen synthase kinase-3, GSK-3β, GSK-3α, GSK-3, GSK3, LY2090314, LY-2090314, LY 2090314, Inhibitor, inhibit

Compound Identifiers

PubChem CID

10029385